Skip to content
Catalyst

N(5)-ethyl-L-glutamineWhat was measured

Measured, with no finding

753 endpoints

Show what was measuredHide what was measured
  • heart rate response to acute stress task

    decreases

    L-Theanine intake resulted in a reduction in the heart rate (HR) and salivary immunoglobulin A (s-IgA) responses to an acute stress task relative to the placebo control condition

    PMID 16930802 · one of two readings recorded this

  • salivary immunoglobulin A response to acute stress task

    decreases

    L-Theanine intake resulted in a reduction in the heart rate (HR) and salivary immunoglobulin A (s-IgA) responses to an acute stress task relative to the placebo control condition

    PMID 16930802 · one of two readings recorded this

  • salivary immunoglobulin A (s-IgA) response and heart rate response to a mental arithmetic acute stress task

    decreases

    Not recorded as a finding: the paper never states the instrument the node requires

    The results showed that L-Theanine intake resulted in a reduction in the heart rate (HR) and salivary immunoglobulin A (s-IgA) responses to an acute stress task relative to the placebo control condition.

    PMID 16930802 · one of two readings recorded this

  • salivary immunoglobulin A (s-IgA) response and heart rate response to a mental arithmetic stress task; assay not stated in the abstract

    decreases

    Not recorded as a finding: the paper never states the instrument the node requires

    The results showed that L-Theanine intake resulted in a reduction in the heart rate (HR) and salivary immunoglobulin A (s-IgA) responses to an acute stress task relative to the placebo control condition.

    PMID 16930802 · one of two readings recorded this

  • sympathetic nervous activation (heart rate variability analysis)

    decreases

    analyses of heart rate variability indicated that the reductions in HR and s-IgA were likely attributable to an attenuation of sympathetic nervous activation

    PMID 16930802 · one of two readings recorded this

  • EEG alpha activity in resting healthy participants with eyes closed, at baseline and 45 to 105 minutes after 50mg L-theanine or placebo

    increases

    Not recorded as a finding: this platform holds no node for the endpoint

    There was a greater increase in alpha activity across time in the L-theanine condition (relative to placebo (p+0.05).

    PMID 18296328 · one of two readings recorded this

  • EEG alpha activity

    increases

    There was a greater increase in alpha activity across time in the L-theanine condition

    PMID 18296328 · one of two readings recorded this

  • EEG alpha activity

    increases

    A second study replicated this effect in participants engaged in passive activity

    PMID 18296328 · one of two readings recorded this

  • EEG alpha frequency band activity, resting eyes closed, at baseline and 45, 60, 75, 90 and 105 minutes after ingestion

    increases

    Not recorded as a finding: this platform holds no node for the endpoint

    There was a greater increase in alpha activity across time in the L-theanine condition (relative to placebo (p+0.05).

    PMID 18296328 · one of two readings recorded this

  • cigarette consumption and proportion of volunteer smokers who stopped smoking after 2 months of tea-filter use

    decreases, cigarette consumption decreased by 56.5%; 31.7% stopped smoking

    Not recorded as a finding: the intervention held more than the compound

    In one trial it was found that after using the tea filters for 2 months, the volunteer smokers decreased their cigarette consumption by 56.5%, and 31.7% of them stopped smoking.

    PMID 20596936 · one of two readings recorded this

  • cigarette consumption and smoking cessation after using tea filters on cigarettes for 2 months

    decreases, cigarette consumption decreased by 56.5%; 31.7% stopped smoking

    Not recorded as a finding: the intervention held more than the compound

    In one trial it was found that after using the tea filters for 2 months, the volunteer smokers decreased their cigarette consumption by 56.5%, and 31.7% of them stopped smoking.

    PMID 20596936 · one of two readings recorded this

  • cigarette consumption

    decreases

    In one trial it was found that after using the tea filters for 2 months, the volunteer smokers decreased their cigarette consumption by 56.5%, and 31.7% of them stopped smoking

    PMID 20596936 · one of two readings recorded this

  • smoking cessation (proportion who stopped smoking)

    increases

    In one trial it was found that after using the tea filters for 2 months, the volunteer smokers decreased their cigarette consumption by 56.5%, and 31.7% of them stopped smoking

    PMID 20596936 · one of two readings recorded this

  • anxiety, Hamilton Anxiety Rating Scale (HARS)

    decreases, p = 0.015

    Not recorded as a finding: node hamilton-anxiety-rating-scale-total-score requires the total score; the abstract says only 'anxiety ... measured by the HARS scale' and never states the total

    Compared with placebo, L-theanine augmentation was associated with reduction of anxiety (P = .015; measured by the HARS scale) and positive (P = .009) and general psychopathology (P < .001) scores (measured by the PANSS 3-dimensional model).

    PMID 21208586 · one of two readings recorded this

  • anxiety

    decreases, p = 0.015

    L-theanine augmentation was associated with reduction of anxiety (P = .015; measured by the HARS scale) and positive (P = .009) and general psychopathology (P < .001) scores

    PMID 21208586 · one of two readings recorded this

  • CANTAB neurocognitive task scores

    no effect

    PANSS negative and CANTAB task scores, general functioning, side effect, and quality of life measures were not affected by L-theanine augmentation

    PMID 21208586 · one of two readings recorded this

  • general functioning, side effect and quality of life measures

    no effect

    PANSS negative and CANTAB task scores, general functioning, side effect, and quality of life measures were not affected by L-theanine augmentation

    PMID 21208586 · one of two readings recorded this

  • general psychopathology score

    decreases, p = 0.001

    L-theanine augmentation was associated with reduction of anxiety (P = .015; measured by the HARS scale) and positive (P = .009) and general psychopathology (P < .001) scores

    PMID 21208586 · one of two readings recorded this

  • PANSS activation factor score (5-dimension model)

    decreases, p = 0.006

    L-theanine produced significant reductions on PANSS positive (P = .004) and activation factor (P = .006) scores compared to placebo

    PMID 21208586 · one of two readings recorded this

  • PANSS negative score, 3-dimension and unspecified model, clinician-rated

    no effect, not affected by L-theanine augmentation

    Not recorded as a finding: Node panss-negative-subscale-score exists, but the sentence pools it with CANTAB, functioning, side effects and quality of life in one agentless-style negation and does not state the model; put down to avoid a one-sided, multi-endpoint quote

    PANSS negative and CANTAB task scores, general functioning, side effect, and quality of life measures were not affected by L-theanine augmentation.

    PMID 21208586 · one of two readings recorded this

  • PANSS negative score

    no effect

    Not recorded as a finding: stated as not affected, but the sentence also lumps CANTAB, functioning, side effects and quality of life and gives no estimate; no clean span for the PANSS negative node

    PANSS negative and CANTAB task scores, general functioning, side effect, and quality of life measures were not affected by L-theanine augmentation.

    PMID 21208586 · one of two readings recorded this

  • PANSS negative score

    no effect

    PANSS negative and CANTAB task scores, general functioning, side effect, and quality of life measures were not affected by L-theanine augmentation

    PMID 21208586 · one of two readings recorded this

  • PANSS positive and activation factor scores, 5-dimension model

    decreases, positive P = .004, activation P = .006

    Not recorded as a finding: 5-dimension factor scores are not the PANSS positive subscale defined by the node (7 items, 3-dimension model); near miss on instrument scoring

    According to the 5-dimension model of psychopathology, L-theanine produced significant reductions on PANSS positive (P = .004) and activation factor (P = .006) scores compared to placebo.

    PMID 21208586 · one of two readings recorded this

  • PANSS positive score (5-dimension model)

    decreases, p = 0.004

    L-theanine produced significant reductions on PANSS positive (P = .004) and activation factor (P = .006) scores compared to placebo

    PMID 21208586 · one of two readings recorded this

  • positive score (3-dimensional model)

    decreases, p = 0.009

    L-theanine augmentation was associated with reduction of anxiety (P = .015; measured by the HARS scale) and positive (P = .009) and general psychopathology (P < .001) scores

    PMID 21208586 · one of two readings recorded this

  • positive symptoms, PANSS positive factor (5-dimension model)

    decreases, significant reductions in PANSS positive and activation factor scores compared with placebo, p = 0.004

    Not recorded as a finding: no outcome node for PANSS positive or activation factor scores

    According to the 5-dimension model of psychopathology, L-theanine produced significant reductions on PANSS positive (P = .004) and activation factor (P = .006) scores compared to placebo.

    PMID 21208586 · one of two readings recorded this

  • psychopathology, PANSS positive and general psychopathology scores (3-dimensional model)

    decreases, positive P = .009; general psychopathology P < .001, p = 0.009

    Not recorded as a finding: no node for PANSS scores

    Compared with placebo, L-theanine augmentation was associated with reduction of anxiety (P = .015; measured by the HARS scale) and positive (P = .009) and general psychopathology (P < .001) scores (measured by the PANSS 3-dimensional model).

    PMID 21208586 · one of two readings recorded this

  • brain theta waves (temporal, frontal, parietal, occipital; eye-open and reading states)

    increases

    Brain theta waves, an indicator of cognitive alertness, were increased significantly in the temporal, frontal, parietal, and occipital areas after 3 hours in the eye-open and reading states

    PMID 21303262 · one of two readings recorded this

  • delayed recognition

    increases, p = 0.0572

    LGNC-07 led to improvements in memory by marginally increasing delayed recognition in the Rey-Kim memory test (P = .0572)

    PMID 21303262 · one of two readings recorded this

  • Rey-Kim memory quotient

    increases

    Stratified analyses showed that LGNC-07 improved memory and selective attention by significantly increasing the Rey-Kim memory quotient and word reading in the subjects with MMSE-K scores of 21-23 (LGNC-07, n = 11; placebo, n = 9)

    PMID 21303262 · one of two readings recorded this

  • word reading (selective attention)

    increases

    Stratified analyses showed that LGNC-07 improved memory and selective attention by significantly increasing the Rey-Kim memory quotient and word reading in the subjects with MMSE-K scores of 21-23 (LGNC-07, n = 11; placebo, n = 9)

    PMID 21303262 · one of two readings recorded this

  • Adherence to test capsules

    Adherence to the test capsules was 93.2% in the catechin/theanine group and 91.9% in the placebo group

    PMID 21338496 · one of two readings recorded this

  • Clinically defined influenza infection, all participants

    clinically defined influenza infection occurred in a total of 17 participants (8.7%), 6 of whom (3.1%) were laboratory confirmed with the type A antigen

    PMID 21338496 · one of two readings recorded this

  • incidence of clinically defined influenza infection (fever 37.8 C or above plus two of cough, sore throat, headache, myalgia), adjusted odds ratio

    decreases, 4.1% versus 13.1%, adjusted OR 0.25 (95% CI 0.07 to 0.76), p = 0.022

    Not recorded as a finding: the intervention held more than the compound

    The incidence of clinically defined influenza infections was significantly lower in the catechin/theanine group (4 participants; 4.1%) than in the placebo group (13 participants; 13.1%) (adjusted OR, 0.25; 95% CI, 0.07 to 0.76, P = 0.022).

    PMID 21338496 · one of two readings recorded this

  • incidence of clinically defined influenza infection (physician diagnosis on fever of 37.8 C or more plus two of cough, sore throat, headache, myalgia), primary outcome; also laboratory-confirmed influenza by antigen assay and time free from influenza

    decreases, adjusted OR, 0.25; 95% CI, 0.07 to 0.76, p = 0.022

    Not recorded as a finding: the intervention held more than the compound

    The incidence of clinically defined influenza infections was significantly lower in the catechin/theanine group (4 participants; 4.1%) than in the placebo group (13 participants; 13.1%) (adjusted OR, 0.25; 95% CI, 0.07 to 0.76, P = 0.022).

    PMID 21338496 · one of two readings recorded this

  • Incidence of clinically defined influenza infection

    decreases, p = 0.022, n = 197

    The incidence of clinically defined influenza infections was significantly lower in the catechin/theanine group (4 participants; 4.1%) than in the placebo group (13 participants; 13.1%) (adjusted OR, 0.25; 95% CI, 0.07 to 0.76, P = 0.022)

    PMID 21338496 · one of two readings recorded this

  • Incidence of laboratory-confirmed influenza infection

    no effect, p = 0.112, n = 197

    The incidence of laboratory-confirmed influenza infection was also lower in the catechin/theanine group (1 participant; 1.0%) than in the placebo group (5 participants; 5.1%), but this difference was not significant (adjusted OR, 0.17; 95% CI, 0.01 to 1.10; P = 0.112)

    PMID 21338496 · one of two readings recorded this

  • Time free from clinically defined influenza infection

    decreases, p = 0.023, n = 197

    The time for which the patient was free from clinically defined influenza infection, estimated with the Cox proportional hazards regression model, was significantly different between the two groups (adjusted hazard ratio, 0.27; 95% CI, 0.09 to 0.84; P = 0.023)

    PMID 21338496 · one of two readings recorded this

  • activation factor and dysphoric mood vs change in cortisol-to-DHEAS*100 molar ratio (share of variance)

    unclear

    the changes in cortisol-to-DHEAS*100 molar ratio accounted for 30% to 34% of the variance in activation factor and dysphoric mood scores and for 15.9% in anxiety scores

    PMID 21617527 · one of two readings recorded this

  • anxiety score vs change in cortisol-to-DHEAS*100 molar ratio (share of variance)

    unclear

    the changes in cortisol-to-DHEAS*100 molar ratio accounted for 30% to 34% of the variance in activation factor and dysphoric mood scores and for 15.9% in anxiety scores

    PMID 21617527 · one of two readings recorded this

  • reduction of anxiety score vs change in serum BDNF (share of variance)

    unclear

    Variability of serum BDNF levels accounted for 26.2% of the total variance in reduction of dysphoric mood and 38.2% in anxiety scores

    PMID 21617527 · one of two readings recorded this

  • reduction of dysphoric mood vs change in serum BDNF (share of variance)

    unclear

    Variability of serum BDNF levels accounted for 26.2% of the total variance in reduction of dysphoric mood and 38.2% in anxiety scores

    PMID 21617527 · one of two readings recorded this

  • regression of symptom improvement on neurochemical changes

    no effect

    Regression models among placebo-treated patients did not reach significant level

    PMID 21617527 · one of two readings recorded this

  • activity during sleep (time awake after sleep onset)

    no effect

    along with a non-significant trend for less activity during sleep (defined as less time awake after sleep onset) compared to those in the placebo group

    PMID 22214254 · one of two readings recorded this

  • Pediatric Sleep Questionnaire correlation with actigraphy

    no effect

    The PSQ data did not correlate significantly to the objective data gathered from actigraphy

    PMID 22214254 · one of two readings recorded this

  • sleep efficiency

    increases

    boys who consumed L-theanine obtained significantly higher sleep percentage and sleep efficiency scores

    PMID 22214254 · one of two readings recorded this

  • sleep latency and other sleep parameters

    no effect

    Sleep latency and other sleep parameters were unchanged

    PMID 22214254 · one of two readings recorded this

  • sleep percentage

    increases

    boys who consumed L-theanine obtained significantly higher sleep percentage and sleep efficiency scores

    PMID 22214254 · one of two readings recorded this

  • L-theanine in plasma, erythrocytes and urine, capsules versus green tea

    no effect, n = 12

    L-Theanine increased in plasma, erythrocytes, and urine with comparable results after both treatments

    PMID 23096008 · one of two readings recorded this

  • plasma and urinary ethylamine and glutamic acid

    increases

    ethylamine and glutamic acid increased in plasma and were excreted by urine after intake of capsules and tea

    PMID 23096008 · one of two readings recorded this

  • plasma L-theanine AUC

    increases, n = 3

    The AUC of L-theanine in plasma increased dose dependently after intake of 50, 100, and 200 mg L-theanine via capsules

    PMID 23096008 · one of two readings recorded this

  • morning pre-practice salivary alpha-amylase activity (sAA)

    decreases, p = 0.032

    In the placebo-group, sAA in the morning (pre-practice sAA) was higher than in theanine-group during the pharmacy practice (p=0.032)

    PMID 24051231 · one of two readings recorded this

  • salivary alpha-amylase activity (sAA), morning, as a marker of sympathetic nervous system activity; subjective stress

    decreases, morning sAA higher in the placebo group than in the theanine group, p = 0.032

    Not recorded as a finding: this platform holds no node for the endpoint

    In the placebo-group, sAA in the morning (pre-practice sAA) was higher than in theanine-group during the pharmacy practice (p=0.032).

    PMID 24051231 · one of two readings recorded this

  • sleeping time versus pre-practice sAA

    decreases

    higher pre-practice sAA was correlated to shorter sleeping time in both groups (p=0.41×10(-3))

    PMID 24051231 · one of two readings recorded this

  • subjective stress (instrument not named in the abstract); salivary alpha-amylase activity as a marker of sympathetic activity

    decreases, p = 0.02

    Not recorded as a finding: the paper never states the instrument the node requires

    Subjective stress was significantly lower in the theanine-group than in the placebo-group (p=0.020).

    PMID 24051231 · one of two readings recorded this

  • subjective stress

    decreases, p = 0.02

    Subjective stress was significantly lower in the theanine-group than in the placebo-group (p=0.020)

    PMID 24051231 · one of two readings recorded this

  • trait anxiety versus pre-practice sAA

    increases, p = 0.015

    students with higher pre-practice sAA showed significantly higher trait anxiety in both groups (p=0.015)

    PMID 24051231 · one of two readings recorded this

  • habituation of startle response

    no effect

    There was no significant relation between the dose of l-theanine and the startle magnitude or the habituation of startle response

    PMID 24372613 · one of two readings recorded this

  • plasma l-theanine concentration

    increases

    The plasma concentrations of l-theanine correlated with the dose of l-theanine

    PMID 24372613 · one of two readings recorded this

  • % PPI (prepulse inhibition)

    increases

    The administration of 200 mg of l-theanine and that of 400 mg, but not 600 mg, significantly increased the % PPI compared to the baseline (0 mg)

    PMID 24372613 · one of two readings recorded this

  • % PPI (prepulse inhibition)

    increases

    The administration of 200 mg of l-theanine and that of 400 mg, but not 600 mg, significantly increased the % PPI compared to the baseline (0 mg)

    PMID 24372613 · one of two readings recorded this

  • % PPI (prepulse inhibition)

    no effect

    The administration of 200 mg of l-theanine and that of 400 mg, but not 600 mg, significantly increased the % PPI compared to the baseline (0 mg)

    PMID 24372613 · one of two readings recorded this

  • sensorimotor gating, percent prepulse inhibition (% PPI) of the startle response

    increases, 200 mg and 400 mg, but not 600 mg, increased % PPI compared with 0 mg

    Not recorded as a finding: this platform holds no node for the endpoint

    The administration of 200 mg of l-theanine and that of 400 mg, but not 600 mg, significantly increased the % PPI compared to the baseline (0 mg).

    PMID 24372613 · one of two readings recorded this

  • startle magnitude

    no effect

    There was no significant relation between the dose of l-theanine and the startle magnitude or the habituation of startle response

    PMID 24372613 · one of two readings recorded this

  • anxiety, Hamilton Scale for Anxiety (HAM-A); negative symptoms, SANS

    decreases

    Not recorded as a finding: the intervention held more than the compound

    Add-on PREG-LT also significantly associated with a reduction of anxiety scores such as anxious mood, tension, and cardiovascular symptoms (HAM-A), and elevation of general functioning (GAF).

    PMID 26218236 · one of two readings recorded this

  • anxiety scores (anxious mood, tension, cardiovascular symptoms)

    decreases

    Add-on PREG-LT also significantly associated with a reduction of anxiety scores such as anxious mood, tension, and cardiovascular symptoms (HAM-A)

    PMID 26218236 · one of two readings recorded this

  • general functioning

    increases

    elevation of general functioning (GAF)

    PMID 26218236 · one of two readings recorded this

  • negative symptoms (blunted affect, alogia, anhedonia)

    decreases

    Negative symptoms such as blunted affect, alogia, and anhedonia (SANS) were found to be significantly improved with moderate effect sizes among patients who received PREG-LT, in comparison with the placebo group

    PMID 26218236 · one of two readings recorded this

  • Alertness response to multi-tasking framework (baseline-adjusted)

    no effect, p = 0.375, n = 26

    Alertness | 26 | −0.72 | 3.86 | 5.28 | 5.69 | 0.375 | 0.267

    PMID 26797633 · one of two readings recorded this

  • Baseline-adjusted ΔΔ stress to multi-tasking framework

    n = 26

    Active | 26 | −13.73 | (18.49) | −6.38 | (23.48)

    PMID 26797633 · one of two readings recorded this

  • Baseline-adjusted ΔΔ stress to multi-tasking framework

    n = 26

    Active | 26 | −13.73 | (18.49) | −6.38 | (23.48)

    PMID 26797633 · one of two readings recorded this

  • Baseline-adjusted ΔΔ stress to multi-tasking framework

    n = 26

    Placebo | 26 | 1.58 | (21.54) | −6.08 | (21.70)

    PMID 26797633 · one of two readings recorded this

  • Baseline-adjusted ΔΔ stress to multi-tasking framework

    n = 26

    Placebo | 26 | 1.58 | (21.54) | −6.08 | (21.70)

    PMID 26797633 · one of two readings recorded this

  • Calmness response to multi-tasking framework (baseline-adjusted)

    no effect, p = 0.624, n = 26

    Calmness | 26 | −0.31 | 3.87 | 0.25 | 0.04 | 0.624 | 0.418

    PMID 26797633 · one of two readings recorded this

  • Change in posterior resting alpha versus trait anxiety score

    increases, p = 0.026, n = 17

    the change in posterior resting alpha was significantly correlated with trait anxiety scores (rs = 0.477, p = 0.026, one-tailed; see Figure 5)

    PMID 26797633 · one of two readings recorded this

  • Cognitive performance on MTF (overall score change from baseline)

    no effect, p = 0.05, n = 25

    Two-way repeated measures ANOVA showed no significant main effect of treatment (F(1,24) = 1.12, p > 0.05)

    PMID 26797633 · one of two readings recorded this

  • Cognitive performance on MTF (overall score change from baseline)

    increases, p = 0.016, n = 25

    however, a significant main effect of assessment time point (F(1,24) = 6.66, p = 0.016)

    PMID 26797633 · one of two readings recorded this

  • Contentedness response to multi-tasking framework (baseline-adjusted)

    no effect, p = 0.885, n = 26

    Contentedness | 26 | −0.56 | 1.41 | 1.99 | 0.62 | 0.885 | 0.152

    PMID 26797633 · one of two readings recorded this

  • Fatigue response to multi-tasking framework (baseline-adjusted)

    no effect, p = 0.663, n = 25

    Fatigue | 25 | −3.32 | −5.96 | −4.80 | −7.44 | 0.663 | 0.999

    PMID 26797633 · one of two readings recorded this

  • Posterior resting alpha activity, active vs placebo

    increases, p = 0.019, n = 9

    posterior resting alpha was significantly higher at the active treatment visit contrasted with placebo for the high trait anxiety group (t(8) = 2.51, p = 0.019, one-tailed)

    PMID 26797633 · one of two readings recorded this

  • Posterior resting alpha activity, active vs placebo

    no effect, p = 0.1, n = 8

    while there was no significant change in the low anxiety group (t(7) = −0.12, p > 0.1)

    PMID 26797633 · one of two readings recorded this

  • Posterior resting relative alpha power (MEG)

    unclear, p = 0.055, n = 17

    Testing mean relative alpha in posterior regions between placebo and active visits showed a non-significant trend towards greater posterior alpha activity after active treatment (t(16) = 1.68, p = 0.055, one-tailed)

    PMID 26797633 · one of two readings recorded this

  • Pre-stressor tranquil-troubled rating at rest (change from baseline)

    n = 26

    Active | 26 | 0.69 | (9.69) | 1.50 | (15.19)

    PMID 26797633 · one of two readings recorded this

  • Pre-stressor tranquil-troubled rating at rest (change from baseline)

    n = 26

    Active | 26 | 0.69 | (9.69) | 1.50 | (15.19)

    PMID 26797633 · one of two readings recorded this

  • Pre-stressor tranquil-troubled rating at rest (change from baseline)

    n = 26

    Placebo | 26 | 4.23 | (13.61) | 2.54 | (11.83)

    PMID 26797633 · one of two readings recorded this

  • Pre-stressor tranquil-troubled rating at rest (change from baseline)

    n = 26

    Placebo | 26 | 4.23 | (13.61) | 2.54 | (11.83)

    PMID 26797633 · one of two readings recorded this

  • Resting state posterior alpha activity

    n = 9

    Active | 42.95 | (14.28) | 45.19 | (10.63)

    PMID 26797633 · one of two readings recorded this

  • Resting state posterior alpha activity

    n = 8

    Active | 42.95 | (14.28) | 45.19 | (10.63)

    PMID 26797633 · one of two readings recorded this

  • Resting state posterior alpha activity

    n = 9

    Placebo | 43.12 | (11.94) | 41.46 | (11.56)

    PMID 26797633 · one of two readings recorded this

  • Resting state posterior alpha activity

    n = 8

    Placebo | 43.12 | (11.94) | 41.46 | (11.56)

    PMID 26797633 · one of two readings recorded this

  • Salivary cortisol response to multi-tasking framework (change pre- to post-stressor)

    no effect, p = 0.05

    Results of Wilcoxon signed ranks tests showed no significant differences in cortisol change between active treatment compared to placebo 1 h post-dose (z = 1.28, p > 0.05, median cortisol response: placebo = −0.19, active = −0.02)

    PMID 26797633 · one of two readings recorded this

  • Salivary cortisol response to multi-tasking framework (change pre- to post-stressor)

    decreases, p = 0.047

    but a significantly lower cortisol response 3 h post-dose for the active treatment visit (z = −1.98, p = 0.047, median cortisol response: placebo = 0.44, active = −0.09)

    PMID 26797633 · one of two readings recorded this

  • State anxiety response to multi-tasking framework (baseline-adjusted)

    no effect, p = 0.201, n = 26

    Anxiety (STAI-S) | 26 | 1.50 | −1.81 | 0.12 | −1.00 | 0.201 | 0.251

    PMID 26797633 · one of two readings recorded this

  • subjective stress response to a 20-minute multi-tasking cognitive stressor, 100-mm stress visual analogue scale, baseline-adjusted change; also salivary cortisol (ELISA), fatigue and STAI-S anxiety

    decreases, p = 0.003, n = 26

    Not recorded as a finding: the intervention held more than the compound

    Paired comparisons showed significantly reduced subjective stress response 1 h post-dose for the active treatment when compared to placebo treatment (p = 0.003), but no significant difference between treatments in stress response at 3 h post-dose (p > 0.05).

    PMID 26797633 · one of two readings recorded this

  • subjective stress response to a multitasking cognitive stressor, 100-mm stress visual analogue scale, baseline-adjusted change

    decreases, stress response reduced 1 h post-dose for active versus placebo; no significant difference at 3 h, p = 0.003

    Not recorded as a finding: the intervention held more than the compound

    Paired comparisons showed significantly reduced subjective stress response 1 h post-dose for the active treatment when compared to placebo treatment (p = 0.003), but no significant difference between treatments in stress response at 3 h post-dose (p > 0.05).

    PMID 26797633 · one of two readings recorded this

  • Subjective stress response to multi-tasking framework (baseline-adjusted ΔΔ stress, VAS)

    decreases, p = 0.003, n = 26

    Paired comparisons showed significantly reduced subjective stress response 1 h post-dose for the active treatment when compared to placebo treatment (p = 0.003)

    PMID 26797633 · one of two readings recorded this

  • Subjective stress response to multi-tasking framework (baseline-adjusted ΔΔ stress, VAS)

    no effect, p = 0.05, n = 26

    but no significant difference between treatments in stress response at 3 h post-dose (p > 0.05)

    PMID 26797633 · one of two readings recorded this

  • Subjective stress response to multi-tasking framework (baseline-adjusted ΔΔ stress, VAS)

    decreases, p = 0.017, n = 26

    a significant assessment time by treatment interaction was observed (F(1,25) = 6.50, p = 0.017, partial η2 = 0.206)

    PMID 26797633 · one of two readings recorded this

  • Subjective stress response to multi-tasking framework (change without baseline adjustment)

    decreases, p = 0.006, n = 26

    showed significantly reduced stress response 1 h post-dose for the active treatment when compared to the placebo treatment (T(25) = 3.03, p = 0.006)

    PMID 26797633 · one of two readings recorded this

  • Mini-Mental State Examination (MMSE)

    increases

    MMSE and PSQ Index significantly improved in the active treatment arm, both versus baseline and versus the parallel arm

    PMID 29188854 · one of two readings recorded this

  • Mini-Mental State Examination score; Perceived Stress Questionnaire index; Self-Rating Depression Scale

    increases, MMSE and PSQ Index significantly improved in the active arm versus baseline and versus the parallel arm, n = 30

    Not recorded as a finding: the intervention held more than the compound

    MMSE and PSQ Index significantly improved in the active treatment arm, both versus baseline and versus the parallel arm.

    PMID 29188854 · one of two readings recorded this

  • Mini-Mental State Examination total score; Perceived Stress Questionnaire Index; Self-Rating Depression Scale

    increases, n = 30

    Not recorded as a finding: the intervention held more than the compound

    MMSE and PSQ Index significantly improved in the active treatment arm, both versus baseline and versus the parallel arm.

    PMID 29188854 · one of two readings recorded this

  • Perceived Stress Questionnaire (PSQ) Index

    unclear

    MMSE and PSQ Index significantly improved in the active treatment arm, both versus baseline and versus the parallel arm

    PMID 29188854 · one of two readings recorded this

  • Self-Rating Depression Scale (SRDS) score

    unclear

    Both groups experienced a significant improving in the SRDS scores

    PMID 29188854 · one of two readings recorded this

  • Blinding: correct guess of treatment allocation

    n = 95

    just over half of all participants (60%) guessed the nature of their treatment correctly (with 49% accuracy in the nutrient enriched condition alone)

    PMID 29215606 · one of two readings recorded this

  • Bond-Lader alertness, main effect of treatment

    increases, p = 0.004, n = 95

    there was a significant main effect of treatment on Bond-Lader ratings of “alertness” (F(1, 93) = 8.919, p = 0.004)

    PMID 29215606 · one of two readings recorded this

  • Cognitive Demand Battery RVIP accuracy

    increases, p = 0.001, n = 95

    with the nutrient enriched intervention leading to improvements in accuracy across Day 1 and Day 56 (F(1, 75) = 47.7, p < 0.001)

    PMID 29215606 · one of two readings recorded this

  • Cognitive Demand Battery RVIP speed

    increases, p = 0.006, n = 95

    improved speed of performance (main treatment effect (F(1, 75) = 8.1, p = 0.006))

    PMID 29215606 · one of two readings recorded this

  • Cognitive Demand Battery Serial 3s correct subtractions

    increases, p = 0.001, n = 95

    Serial 3s (F(1, 93) = 24.4, p < 0.001); Serial 7s (F(1, 93) = 13.4, p < 0.001)

    PMID 29215606 · one of two readings recorded this

  • Cognitive Demand Battery Serial 7s correct subtractions

    increases, p = 0.001, n = 95

    Serial 3s (F(1, 93) = 24.4, p < 0.001); Serial 7s (F(1, 93) = 13.4, p < 0.001)

    PMID 29215606 · one of two readings recorded this

  • COMPASS cognitive tasks (RVIP accuracy and speed, Corsi blocks span, serial subtractions, word recall), Bond-Lader alertness, mental fatigue VAS

    increases, Corsi blocks span score, main effect of treatment across post-dose assessments, p = 0.004

    Not recorded as a finding: the intervention held more than the compound

    With regard to working memory, there was a significant main effect on the Corsi blocks span score (F(1, 93) = 8.49, p = 0.004), with the nutrient enriched treatment being associated with improved working memory capacity across post-dose assessments on Day 1 and Day 56.

    PMID 29215606 · one of two readings recorded this

  • Corsi blocks span score, main effect of treatment

    increases, p = 0.004, n = 95

    there was a significant main effect on the Corsi blocks span score (F(1, 93) = 8.49, p = 0.004)

    PMID 29215606 · one of two readings recorded this

  • Delayed Word Recall errors, main effect of treatment

    decreases, p = 0.029, n = 95

    main effects seen in terms of a reduced number of errors committed on the Delayed Word Recall task (F(1, 92) = 4.94, p = 0.029)

    PMID 29215606 · one of two readings recorded this

  • Numeric Working Memory accuracy, assessment x treatment interaction

    no effect, p = 0.04, n = 95

    There was also a significant assessment × treatment interaction (F(1, 93) = 4.345, p = 0.04) with regards the accuracy of performing the Numeric Working Memory task

    PMID 29215606 · one of two readings recorded this

  • Peg and Ball errors, post-hoc comparison

    decreases, p = 0.05, n = 95

    increased accuracy of performance following the nutrient enriched bar which was restricted to the 40 min post-dose assessment (t (93) = 2.55, p < 0.05)

    PMID 29215606 · one of two readings recorded this

  • Peg and Ball errors, treatment x assessment interaction

    modulates, p = 0.036, n = 95

    there was also significant treatment × assessment interaction (F(1, 93) = 4.55, p = 0.036) with regards the number of errors committed during the same task

    PMID 29215606 · one of two readings recorded this

  • Peg and Ball thinking time, post-hoc comparison

    decreases, p = 0.01, n = 95

    participants required a shorter amount of time to plan their moves following consumption of the nutrient enriched intervention but only on Day 56 (t (93) = 3.57, p < 0.01)

    PMID 29215606 · one of two readings recorded this

  • Peg and Ball thinking time, treatment x day interaction

    modulates, p = 0.014, n = 95

    there was a significant treatment × day interaction (F(1, 93) = 6.33, p = 0.014) on the Peg and Ball task in terms of “thinking time”

    PMID 29215606 · one of two readings recorded this

  • Picture Recognition accuracy, post-hoc comparison

    decreases, p = 0.05, n = 95

    this effect represented a decrement in performance on Day 1 (t (93) = 2.44, p < 0.05), with a trend towards improved performance on Day 56 (t (93) = 1.99, p < 0.1)

    PMID 29215606 · one of two readings recorded this

  • Picture Recognition accuracy, post-hoc comparison

    unclear, p = 0.1, n = 95

    this effect represented a decrement in performance on Day 1 (t (93) = 2.44, p < 0.05), with a trend towards improved performance on Day 56 (t (93) = 1.99, p < 0.1)

    PMID 29215606 · one of two readings recorded this

  • Picture Recognition accuracy, treatment x day interaction

    modulates, p = 0.015, n = 95

    there was also a significant treatment × day interaction (F(1, 90) = 6.15, p = 0.015) in terms of accuracy of performance

    PMID 29215606 · one of two readings recorded this

  • Picture Recognition speed, main effect of treatment

    increases, p = 0.002, n = 95

    improved speed of performing the Picture Recognition task (F(1, 90) = 9.9, p = 0.002) across post-dose assessments on Day 1 and Day 56

    PMID 29215606 · one of two readings recorded this

  • Pure chronic effect on pre-dose performance, any task

    no effect, n = 95

    There were no significant differences in performance for any task during the pre-dose assessment on Day 56 that would indicate a chronic effect of treatment in the absence of any acute effects

    PMID 29215606 · one of two readings recorded this

  • RVIP accuracy, assessment x treatment interaction

    modulates, p = 0.014, n = 95

    There was also a significant assessment x treatment interaction (F(1, 87) = 6.29, p = 0.014) with regards the same measure

    PMID 29215606 · one of two readings recorded this

  • RVIP accuracy, main effect of treatment

    increases, p = 0.001, n = 95

    there was a significant main effect of treatment with regards the accuracy of performing the Rapid Visual Information Processing (RVIP) task (F(1, 87) = 24.74, p < 0.001)

    PMID 29215606 · one of two readings recorded this

  • RVIP accuracy, post-hoc comparison

    increases, p = 0.001, n = 95

    accuracy was improved during both assessments (40 min (t (87) = 4.65, p < 0.001), 160 min (t (93) = 7.59, p < 0.001))

    PMID 29215606 · one of two readings recorded this

  • RVIP accuracy, post-hoc comparison

    increases, p = 0.001, n = 95

    accuracy was improved during both assessments (40 min (t (87) = 4.65, p < 0.001), 160 min (t (93) = 7.59, p < 0.001))

    PMID 29215606 · one of two readings recorded this

  • RVIP speed, main effect of treatment

    increases, p = 0.002, n = 95

    With regards the speed of performing the RVIP task, there was also a significant main effect of treatment (F(1, 87) = 10.29, p = 0.002)

    PMID 29215606 · one of two readings recorded this

  • Subjective mental fatigue during Cognitive Demand Battery

    decreases, p = 0.001, n = 95

    subjective ratings of mental fatigue (measured after each repetition of the three CDB tasks) was also significantly reduced across Days 1 and 56 following the nutrient enriched intervention (F(3, 279) = 22.5, p < 0.001)

    PMID 29215606 · one of two readings recorded this

  • cognitive impairment

    unclear

    the current literature supports the use of Ginkgo biloba, resveratrol, epigallocatechin-3-gallate and l-theanine, Theobroma cacao, Bacopa monnieri, Crocus sativus and curcumin

    PMID 29289576 · one of two readings recorded this

  • urinary 3-methyl-2-oxovalerate level

    increases

    The consumption of the HCT resulted in the excretion of theanine, epicatechin, pyrogallol sulfate, and higher levels of 3-methyl-2-oxovalerate and succinate

    PMID 30574780 · one of two readings recorded this

  • urinary epicatechin excretion

    increases

    The consumption of the HCT resulted in the excretion of theanine, epicatechin, pyrogallol sulfate, and higher levels of 3-methyl-2-oxovalerate and succinate

    PMID 30574780 · one of two readings recorded this

  • urinary excretion of theanine and other metabolites by untargeted 1H NMR metabolomics after a high-catechin tea

    increases, consumption of the high-catechin tea resulted in excretion of theanine

    Not recorded as a finding: the compound is what was measured, not what was given

    The consumption of the HCT resulted in the excretion of theanine, epicatechin, pyrogallol sulfate, and higher levels of 3-methyl-2-oxovalerate and succinate, as well as unknown compounds.

    PMID 30574780 · one of two readings recorded this

  • urinary pyrogallol sulfate excretion

    increases

    The consumption of the HCT resulted in the excretion of theanine, epicatechin, pyrogallol sulfate, and higher levels of 3-methyl-2-oxovalerate and succinate

    PMID 30574780 · one of two readings recorded this

  • urinary succinate level

    increases

    The consumption of the HCT resulted in the excretion of theanine, epicatechin, pyrogallol sulfate, and higher levels of 3-methyl-2-oxovalerate and succinate

    PMID 30574780 · one of two readings recorded this

  • urinary theanine excretion

    increases

    The consumption of the HCT resulted in the excretion of theanine, epicatechin, pyrogallol sulfate, and higher levels of 3-methyl-2-oxovalerate and succinate

    PMID 30574780 · one of two readings recorded this

  • anxiety reduction on the HAMA

    no effect, p = 0.73

    adjunctive L-theanine did not outperform placebo for anxiety reduction on the HAMA (p = 0.73) nor insomnia severity on the Insomnia Severity Index (ISI; p = 0.35)

    PMID 30580081 · one of two readings recorded this

  • insomnia severity on the Insomnia Severity Index

    no effect, p = 0.35

    adjunctive L-theanine did not outperform placebo for anxiety reduction on the HAMA (p = 0.73) nor insomnia severity on the Insomnia Severity Index (ISI; p = 0.35)

    PMID 30580081 · one of two readings recorded this

  • insomnia severity on the Insomnia Severity Index

    unclear, p = 0.007

    a separation in favour of L-theanine was noted on the ISI in those with non-clinical levels of insomnia symptoms (ISI ≤ 14; p = 0.007)

    PMID 30580081 · one of two readings recorded this

  • modified emotional Stroop

    no effect

    No significant cognitive effects (trail making time and the modified emotional Stroop) were revealed

    PMID 30580081 · one of two readings recorded this

  • self-reported sleep satisfaction (ISI item 4)

    increases, p = 0.015

    LT treated participants reported greater self-reported sleep satisfaction than placebo (ISI item 4; p = 0.015)

    PMID 30580081 · one of two readings recorded this

  • sleep satisfaction, Insomnia Severity Index item 4

    increases, greater self-reported sleep satisfaction than placebo, p = 0.015

    Not recorded as a finding: single ISI item, not the total score the insomnia node requires; no node for an item score

    However, LT treated participants reported greater self-reported sleep satisfaction than placebo (ISI item 4; p = 0.015).

    PMID 30580081 · one of two readings recorded this

  • sleep satisfaction, ISI item 4 (single item)

    increases, greater self-reported sleep satisfaction than placebo, p = 0.015

    Not recorded as a finding: no node for a single ISI item; node requires the 7-item total

    However, LT treated participants reported greater self-reported sleep satisfaction than placebo (ISI item 4; p = 0.015).

    PMID 30580081 · one of two readings recorded this

  • trail making time

    no effect

    No significant cognitive effects (trail making time and the modified emotional Stroop) were revealed

    PMID 30580081 · one of two readings recorded this

  • 2000-m ergometer mean power output

    no effect, n = 20

    Power (Watt) | 436 ± 28.5 | 445 ± 17.52 | 401 ± 31.48 | 411 ± 36.69

    PMID 30770758 · one of two readings recorded this

  • 2000-m ergometer relative power output

    no effect, n = 20

    (W x kg−1) | 5.01 ± 0.37 | 5.02 ± 0.28 | 4.81 ± 0.44 | 4.93 ± 0.22

    PMID 30770758 · one of two readings recorded this

  • 2000-m ergometer time

    no effect, n = 20

    Time (s) | 371.3 ± 8.47 | 368.7 ± 5.22 | 382.1 ± 12.98 | 379.2 ± 11.78

    PMID 30770758 · one of two readings recorded this

  • 2000-m rowing ergometer time trial, total run time (and mean power output), before versus after 6 weeks of 150 mg L-theanine extract or placebo; the only sentence reports intragroup differences and no between-arm sentence gives the time

    no effect

    Not recorded as a finding: the result compares a group with itself, not with a control

    No significant intragroup differences were found in mean power output and total run time during the 2000-m test performed at the beginning and at the end of the training camp (1st and 2nd examination, respectively).

    PMID 30770758 · one of two readings recorded this

  • Blood lactate maximum (LAmax) around the 2000-m test

    no effect, n = 20

    LAmax (mmol x L−1)a | 15.1 ± 2.31 | 11.6 ± 2.42 | 14.1 ± 3.18 | 12.3 ± 4.13

    PMID 30770758 · one of two readings recorded this

  • Blood lactate minimum (LAmin) around the 2000-m test

    no effect, n = 20

    LAmin (mmol x L−1)a | 1.6 ± 0.37 | 1.5 ± 0.81 | 1.8 ± 0.73 | 1.6 ± 0.25

    PMID 30770758 · one of two readings recorded this

  • CTL count

    no effect, p = 0.294, n = 20

    Nevertheless, the main effect of the supplementation on CTL count did not turn out to be statistically significant on ANOVA (p = 0.294)

    PMID 30770758 · one of two readings recorded this

  • Granulocyte percentage

    no effect, p = 0.8803, n = 20

    Granulocytes [%] | LTE | 46.0 ± 10.81 | 47.6 ± 3.85 | 52.6 ± 5.53 | 46.4 ± 3.69 | 41.9 ± 5.37 | 51.3 ± 6.25† | < 0.0001 | 0.8803 | 0.4637

    PMID 30770758 · one of two readings recorded this

  • Granulocyte percentage

    no effect, n = 20

    Pla | 48.9 ± 5.68 | 47.8 ± 6.22 | 48.8 ± 5.44 | 45.5 ± 3.58 | 43.4 ± 7.35 | 49.9 ± 6.04

    PMID 30770758 · one of two readings recorded this

  • Lymphocyte percentage

    no effect, p = 0.5098, n = 20

    Lymphocytes [%] | LTE | 42.73 ± 7.85 | 44.59 ± 4.21 | 38.44 ± 6.04 | 43.48 ± 3.08 | 48.36 ± 4.93 | 38.79 ± 5.35† | < 0.0001 | 0.5098 | 0.5920

    PMID 30770758 · one of two readings recorded this

  • Lymphocyte percentage

    no effect, n = 20

    Pla | 43.19 ± 5.32 | 45.13 ± 6.59 | 42.83 ± 6.02 | 44.98 ± 3.39 | 47.62 ± 6.99 | 40.17 ± 6.19†

    PMID 30770758 · one of two readings recorded this

  • Serum IFN-γ concentration

    no effect, p = 0.172, n = 20

    Statistical analysis showed that supplementation with L-theanine did not exert a significant effect on IFN-γ levels (main effect, p = 0.172)

    PMID 30770758 · one of two readings recorded this

  • Serum IL-10 concentration

    no effect, p = 0.943, n = 20

    Although supplementation with L-theanine did not exert a significant effect on IL-10 level (main effect, p = 0.943)

    PMID 30770758 · one of two readings recorded this

  • Serum IL-2 concentration

    no effect, p = 0.981, n = 20

    this parameter turned out to be independent of L-theanine supplementation (ANOVA, main effect, p = 0.981)

    PMID 30770758 · one of two readings recorded this

  • Serum IL-4 concentration

    no effect, p = 0.508, n = 20

    This parameter turned out to be modulated by neither physical exercise (main effect, p = 0.662) nor supplementation (main effect, p = 0.508)

    PMID 30770758 · one of two readings recorded this

  • Tδγ cell count

    no effect, p = 0.156, n = 20

    The main effect of the supplementation on Tδγ cell count did not turn out to be statistically significant (p = 0.156)

    PMID 30770758 · one of two readings recorded this

  • Total antioxidant capacity (TAC)

    no effect, p = 0.2035, n = 20

    TAC (mmol/l) | LTE | 2.36 ± 0.38 | 1.78 ± 0.40* | 2.11 ± 0.55 | 2.22 ± 0.44 | 1.80 ± 0.35 | 2.43 ± 0.41† | < 0.0001 | 0.2035 | 0.5617

    PMID 30770758 · one of two readings recorded this

  • Total antioxidant capacity (TAC)

    no effect, n = 20

    Pla | 2.49 ± 0.22 | 1.65 ± 0.28* | 2.18 ± 0.42 | 1.87 ± 0.46 | 1.69 ± 0.24 | 2.39 ± 0.46

    PMID 30770758 · one of two readings recorded this

  • Treg count

    no effect, p = 0.149, n = 20

    ANOVA demonstrated that supplementation with L-theanine did not exert a statistically significant effect on Treg count (main effect, p = 0.149)

    PMID 30770758 · one of two readings recorded this

  • Treg to CTL ratio

    no effect, p = 0.771, n = 20

    Statistical analysis showed that the values of Treg to CTL ratio were modulated by the exercise, but not by the supplementation (p < 0.001 and p = 0.771, respectively; Fig. 4d)

    PMID 30770758 · one of two readings recorded this

  • Treg to NK ratio

    no effect, p = 0.233, n = 20

    Statistical analysis showed that the values of Treg to NK ratio were influenced by physical exercise (p < 0.001), but not by the supplementation (p = 0.233)

    PMID 30770758 · one of two readings recorded this

  • Treg to (NK + Tδγ + CTL) ratio

    no effect, p = 0.053, n = 20

    ANOVA showed that the main effect of the supplementation on Treg to (NK+ Tδγ + CTL) ratio was not statistically significant (p = 0.053)

    PMID 30770758 · one of two readings recorded this

  • Treg to Tδγ ratio

    no effect, p = 0.156, n = 20

    but not by the LTE supplementation (main effect, p = 0.156)

    PMID 30770758 · one of two readings recorded this

  • White blood cell count

    no effect, p = 0.2236, n = 20

    WBC [109/L] | LTE | 6.81 ± 1.47 | 11.16 ± 1.52* | 6.53 ± 1.04† | 6.25 ± 1.17 | 11.12 ± 1.96* | 6.46 ± 1.51† | < 0.0001 | 0.2236 | 0.7378

    PMID 30770758 · one of two readings recorded this

  • White blood cell count

    no effect, n = 20

    Pla | 5.98 ± 1.27 | 10.1 ± 1.56* | 5.75 ± 0.75† | 6.03 ± 1.13 | 10.83 ± 1.91* | 6.0 ± 0.74†

    PMID 30770758 · one of two readings recorded this

  • BACS executive function

    increases, p = 0.031

    The BACS verbal fluency, especially letter fluency (p = 0.001), and executive function scores were significantly increased after L-theanine administration (p = 0.001 and 0.031, respectively

    PMID 31623400 · one of two readings recorded this

  • BACS letter fluency

    increases, p = 0.001

    The BACS verbal fluency, especially letter fluency (p = 0.001), and executive function scores were significantly increased after L-theanine administration (p = 0.001 and 0.031, respectively

    PMID 31623400 · one of two readings recorded this

  • BACS verbal fluency

    increases, p = 0.001

    The BACS verbal fluency, especially letter fluency (p = 0.001), and executive function scores were significantly increased after L-theanine administration (p = 0.001 and 0.031, respectively

    PMID 31623400 · one of two readings recorded this

  • change in BACS executive function

    increases, p = 0.048, n = 21

    The results were essentially unchanged (n = 21; verbal fluency: p = 0.023, letter fluency: p = 0.040, and executive function: p = 0.048; Supplementary Table S1)

    PMID 31623400 · one of two readings recorded this

  • change in BACS executive function

    unclear, p = 0.062

    the BACS executive function score improvement tended to be greater in the L-theanine period than in the placebo period among the lower half of the group (p = 0.062)

    PMID 31623400 · one of two readings recorded this

  • change in BACS letter fluency

    increases, p = 0.04, n = 21

    The results were essentially unchanged (n = 21; verbal fluency: p = 0.023, letter fluency: p = 0.040, and executive function: p = 0.048; Supplementary Table S1)

    PMID 31623400 · one of two readings recorded this

  • change in BACS letter fluency

    increases, p = 0.002

    improvement in the BACS verbal fluency (p = 0.002), especially letter fluency (p = 0.002), score was significantly greater during the L-theanine period than the placebo period

    PMID 31623400 · one of two readings recorded this

  • change in BACS verbal fluency

    increases, p = 0.023, n = 21

    The results were essentially unchanged (n = 21; verbal fluency: p = 0.023, letter fluency: p = 0.040, and executive function: p = 0.048; Supplementary Table S1)

    PMID 31623400 · one of two readings recorded this

  • change in BACS verbal fluency

    increases, p = 0.002

    improvement in the BACS verbal fluency (p = 0.002), especially letter fluency (p = 0.002), score was significantly greater during the L-theanine period than the placebo period

    PMID 31623400 · one of two readings recorded this

  • change in cognitive function scores

    no effect

    When score changes were compared between the L-theanine and placebo administrations, no significant difference was found for any cognitive function

    PMID 31623400 · one of two readings recorded this

  • change in PSQI sleep disturbance subscale

    decreases, p = 0.046

    changes in the PSQI sleep latency, sleep disturbance, and use of sleep medication subscales were significantly greater (p = 0.0499, 0.046, and 0.047, respectively)

    PMID 31623400 · one of two readings recorded this

  • change in PSQI sleep latency subscale

    decreases, p = 0.0499

    changes in the PSQI sleep latency, sleep disturbance, and use of sleep medication subscales were significantly greater (p = 0.0499, 0.046, and 0.047, respectively)

    PMID 31623400 · one of two readings recorded this

  • change in PSQI total score

    unclear, p = 0.073

    those in the SDS and PSQI scores showed a non-statistically significant trend towards greater improvement (p = 0.084 and 0.073, respectively)

    PMID 31623400 · one of two readings recorded this

  • change in PSQI use of sleep medication subscale

    decreases, p = 0.047

    changes in the PSQI sleep latency, sleep disturbance, and use of sleep medication subscales were significantly greater (p = 0.0499, 0.046, and 0.047, respectively)

    PMID 31623400 · one of two readings recorded this

  • change in SDS score

    unclear, p = 0.084

    those in the SDS and PSQI scores showed a non-statistically significant trend towards greater improvement (p = 0.084 and 0.073, respectively)

    PMID 31623400 · one of two readings recorded this

  • other biochemical indices

    no effect

    No other significantly altered indices were found after either L-theanine or placebo administration

    PMID 31623400 · one of two readings recorded this

  • PSQI daytime dysfunction subscale

    decreases, p = 0.022

    the scores of “sleep latency” and “daytime dysfunction” significantly improved in response to L-theanine administration (p = 0.036 and 0.022, respectively)

    PMID 31623400 · one of two readings recorded this

  • PSQI sleep latency subscale

    decreases, p = 0.036

    the scores of “sleep latency” and “daytime dysfunction” significantly improved in response to L-theanine administration (p = 0.036 and 0.022, respectively)

    PMID 31623400 · one of two readings recorded this

  • PSQI total score

    decreases, p = 0.013

    The SDS, STAI-trait (T), and PSQI scores were significantly improved after L-theanine administration (p = 0.019, 0.006, and 0.013, respectively

    PMID 31623400 · one of two readings recorded this

  • SDS score

    decreases, p = 0.019

    The SDS, STAI-trait (T), and PSQI scores were significantly improved after L-theanine administration (p = 0.019, 0.006, and 0.013, respectively

    PMID 31623400 · one of two readings recorded this

  • serum L-theanine concentration

    increases, p = 0.028

    There was a significant difference in the serum L-theanine concentration between the L-theanine and placebo administrations (p = 0.028)

    PMID 31623400 · one of two readings recorded this

  • serum L-theanine concentration

    increases, p = 0.002

    The serum L-theanine concentration was significantly increased after L-theanine administration (p = 0.002)

    PMID 31623400 · one of two readings recorded this

  • STAI-trait score

    decreases, p = 0.006

    The SDS, STAI-trait (T), and PSQI scores were significantly improved after L-theanine administration (p = 0.019, 0.006, and 0.013, respectively

    PMID 31623400 · one of two readings recorded this

  • stress-related symptom scores (SDS, STAI-T, PSQI)

    no effect

    In contrast, there was no significant difference after placebo administration

    PMID 31623400 · one of two readings recorded this

  • Trail Making Test A

    decreases, p = 0.042

    the Trail Making Test A and B scores were significantly improved after placebo administration (p = 0.042 and 0.038, respectively)

    PMID 31623400 · one of two readings recorded this

  • Trail Making Test B

    decreases, p = 0.038

    the Trail Making Test A and B scores were significantly improved after placebo administration (p = 0.042 and 0.038, respectively)

    PMID 31623400 · one of two readings recorded this

  • stress and anxiety levels

    decreases

    Our findings suggest that supplementation of 200-400 mg/day of L-THE may assist in the reduction of stress and anxiety in people exposed to stressful conditions

    PMID 31758301 · one of two readings recorded this

  • continuous finger-cuff systolic and diastolic blood pressure, area under the curve over 90 minutes after eating sorbet with or without 200 mg L-theanine; heart rate and HRV

    no effect, systolic BP AUC, between-group, entire 90 minute period, p = 0.839

    Not recorded as a finding: a node exists but the paper states a different instrument or population

    For systolic BP, between-group analysis for AUC did not demonstrate any significant effects for the entire 90 minute period (median; 1323 mmHg, 25th; 1157 mmHg, 75th; 1462 mmHg, p = 0.839).

    PMID 32210015 · one of two readings recorded this

  • Diastolic blood pressure AUC 0-90 min

    no effect, p = 0.922, n = 11

    For diastolic BP, between-group AUC analysis showed no significant differences during the entirety of the 90 minutes amongst either of the conditions (median; 1323 mmHg, 25th; 1157 mmHg, 75th; 1462 mmHg, p = 0.922)

    PMID 32210015 · one of two readings recorded this

  • Heart rate AUC 0-90 min

    no effect, p = 0.996, n = 11

    Between-group AUC analysis showed no significant differences during the entire 90 minutes between either of the conditions (median; 1325, 25th; 1222, 75th; 1385, p = 0.996)

    PMID 32210015 · one of two readings recorded this

  • Heart rate, within-group analysis

    modulates, p = 0.003, n = 11

    within-group analysis showed significant differences within the baseline group (p = 0.003) as well as within the ms-L-THE group (p = 0.066)

    PMID 32210015 · one of two readings recorded this

The whole record — 753 rows